FDA OCE commentary: Cancer burden facing Asian Americans partly caused by racism

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A commentary authored by seven researchers who participated in the FDA Oncology Center of Excellence “Conversations on Cancer,” held July 29, 2021, discussed the significant cancer disparities facing Asian Americans. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases. 
FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login